BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 32527540)

  • 1. Discovery of triazolo [1,5-a] pyridine derivatives as novel JAK1/2 inhibitors.
    Lu K; Wu W; Zhang C; Liu Z; Xiao B; Yuan Z; Li A; Chen D; Zhai X; Jiang Y
    Bioorg Med Chem Lett; 2020 Jul; 30(14):127225. PubMed ID: 32527540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure-based discovery of C-2 substituted imidazo-pyrrolopyridine JAK1 inhibitors with improved selectivity over JAK2.
    Labadie S; Dragovich PS; Barrett K; Blair WS; Bergeron P; Chang C; Deshmukh G; Eigenbrot C; Ghilardi N; Gibbons P; Hurley CA; Johnson A; Kenny JR; Kohli PB; Kulagowski JJ; Liimatta M; Lupardus PJ; Mendonca R; Murray JM; Pulk R; Shia S; Steffek M; Ubhayakar S; Ultsch M; van Abbema A; Ward S; Zak M
    Bioorg Med Chem Lett; 2012 Dec; 22(24):7627-33. PubMed ID: 23107482
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of imidazo-pyrrolopyridines as novel and potent JAK1 inhibitors.
    Kulagowski JJ; Blair W; Bull RJ; Chang C; Deshmukh G; Dyke HJ; Eigenbrot C; Ghilardi N; Gibbons P; Harrison TK; Hewitt PR; Liimatta M; Hurley CA; Johnson A; Johnson T; Kenny JR; Bir Kohli P; Maxey RJ; Mendonca R; Mortara K; Murray J; Narukulla R; Shia S; Steffek M; Ubhayakar S; Ultsch M; van Abbema A; Ward SI; Waszkowycz B; Zak M
    J Med Chem; 2012 Jun; 55(12):5901-21. PubMed ID: 22591402
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The discovery of 2,5-isomers of triazole-pyrrolopyrimidine as selective Janus kinase 2 (JAK2) inhibitors versus JAK1 and JAK3.
    Lee SM; Yoon KB; Lee HJ; Kim J; Chung YK; Cho WJ; Mukai C; Choi S; Kang KW; Han SY; Ko H; Kim YC
    Bioorg Med Chem; 2016 Nov; 24(21):5036-5046. PubMed ID: 27555284
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of 3,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-2(1H)-one derivatives as novel JAK inhibitors.
    Yamagishi H; Shirakami S; Nakajima Y; Tanaka A; Takahashi F; Hamaguchi H; Hatanaka K; Moritomo A; Inami M; Higashi Y; Inoue T
    Bioorg Med Chem; 2015 Aug; 23(15):4846-4859. PubMed ID: 26059596
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of imidazopyrrolopyridines derivatives as novel and selective inhibitors of JAK2.
    Xu P; Shen P; Wang H; Qin L; Ren J; Sun Q; Ge R; Bian J; Zhong Y; Li Z; Wang J; Qiu Z
    Eur J Med Chem; 2021 Jun; 218():113394. PubMed ID: 33813153
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design and evaluation of novel 8-oxo-pyridopyrimidine Jak1/2 inhibitors.
    Labadie S; Barrett K; Blair WS; Chang C; Deshmukh G; Eigenbrot C; Gibbons P; Johnson A; Kenny JR; Kohli PB; Liimatta M; Lupardus PJ; Shia S; Steffek M; Ubhayakar S; van Abbema A; Zak M
    Bioorg Med Chem Lett; 2013 Nov; 23(21):5923-30. PubMed ID: 24042009
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diamino-1,2,4-triazole derivatives are selective inhibitors of TYK2 and JAK1 over JAK2 and JAK3.
    Malerich JP; Lam JS; Hart B; Fine RM; Klebansky B; Tanga MJ; D'Andrea A
    Bioorg Med Chem Lett; 2010 Dec; 20(24):7454-7. PubMed ID: 21106455
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure activity optimization of 6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyrazines as Jak1 kinase inhibitors.
    Friedman M; Frank KE; Aguirre A; Argiriadi MA; Davis H; Edmunds JJ; George DM; George JS; Goedken E; Fiamengo B; Hyland D; Li B; Murtaza A; Morytko M; Somal G; Stewart K; Tarcsa E; Van Epps S; Voss J; Wang L; Woller K; Wishart N
    Bioorg Med Chem Lett; 2015 Oct; 25(20):4399-404. PubMed ID: 26372653
    [TBL] [Abstract][Full Text] [Related]  

  • 10. INCB16562, a JAK1/2 selective inhibitor, is efficacious against multiple myeloma cells and reverses the protective effects of cytokine and stromal cell support.
    Li J; Favata M; Kelley JA; Caulder E; Thomas B; Wen X; Sparks RB; Arvanitis A; Rogers JD; Combs AP; Vaddi K; Solomon KA; Scherle PA; Newton R; Fridman JS
    Neoplasia; 2010 Jan; 12(1):28-38. PubMed ID: 20072651
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 4-Amino-pyrrolopyridine-5-carboxamide: a novel scaffold for JAK1-selective inhibitors.
    Shin H; Kim MK; Chong Y
    Chem Pharm Bull (Tokyo); 2014; 62(3):217-20. PubMed ID: 24583775
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery and Optimization of a Novel Series of Highly Selective JAK1 Kinase Inhibitors.
    Grimster NP; Anderson E; Alimzhanov M; Bebernitz G; Bell K; Chuaqui C; Deegan T; Ferguson AD; Gero T; Harsch A; Huszar D; Kawatkar A; Kettle JG; Lyne P; Read JA; Rivard Costa C; Ruston L; Schroeder P; Shi J; Su Q; Throner S; Toader D; Vasbinder M; Woessner R; Wang H; Wu A; Ye M; Zheng W; Zinda M
    J Med Chem; 2018 Jun; 61(12):5235-5244. PubMed ID: 29856615
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of azabenzimidazoles as potent JAK1 selective inhibitors.
    Vasbinder MM; Alimzhanov M; Augustin M; Bebernitz G; Bell K; Chuaqui C; Deegan T; Ferguson AD; Goodwin K; Huszar D; Kawatkar A; Kawatkar S; Read J; Shi J; Steinbacher S; Steuber H; Su Q; Toader D; Wang H; Woessner R; Wu A; Ye M; Zinda M
    Bioorg Med Chem Lett; 2016 Jan; 26(1):60-7. PubMed ID: 26614408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 9H-Carbazole-1-carboxamides as potent and selective JAK2 inhibitors.
    Zimmermann K; Sang X; Mastalerz HA; Johnson WL; Zhang G; Liu Q; Batt D; Lombardo LJ; Vyas D; Trainor GL; Tokarski JS; Lorenzi MV; You D; Gottardis MM; Lippy J; Khan J; Sack JS; Purandare AV
    Bioorg Med Chem Lett; 2015 Jul; 25(14):2809-12. PubMed ID: 25987372
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery and Biological Evaluation of
    Park E; Lee SJ; Moon H; Park J; Jeon H; Hwang JS; Hwang H; Hong KB; Han SH; Choi S; Kang S
    J Med Chem; 2021 Jan; 64(2):958-979. PubMed ID: 33428419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery and optimization of 2-aminopyridine derivatives as novel and selective JAK2 inhibitors.
    Ma X; Diao Y; Ge H; Xu F; Zhu L; Zhao Z; Li H
    Bioorg Med Chem Lett; 2020 Apr; 30(8):127048. PubMed ID: 32122740
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of potent and efficacious pyrrolopyridazines as dual JAK1/3 inhibitors.
    Hynes J; Wu H; Kempson J; Duan JJ; Lu Z; Jiang B; Stachura S; Tokarski JS; Sack JS; Khan JA; Lippy JS; Zhang RF; Pitt S; Shen G; Gillooly K; McIntyre K; Carter PH; Barrish JC; Nadler SG; Salter-Cid LM; Fura A; Schieven GL; Pitts WJ; Wrobleski ST
    Bioorg Med Chem Lett; 2017 Jul; 27(14):3101-3106. PubMed ID: 28539220
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Linear propargylic alcohol functionality attached to the indazole-7-carboxamide as a JAK1-specific linear probe group.
    Kim MK; Shin H; Cho SY; Chong Y
    Bioorg Med Chem; 2014 Feb; 22(3):1156-62. PubMed ID: 24398382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel JAK1-selective benzimidazole inhibitors with enhanced membrane permeability.
    Kim H; Kim MK; Choo H; Chong Y
    Bioorg Med Chem Lett; 2016 Jul; 26(14):3213-3215. PubMed ID: 27261178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of selective inhibitors for the treatment of rheumatoid arthritis: (R)-3-(3-(Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)-3-oxopropanenitrile as a JAK1-selective inhibitor.
    Chough C; Joung M; Lee S; Lee J; Kim JH; Kim BM
    Bioorg Med Chem; 2018 May; 26(8):1495-1510. PubMed ID: 29452839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.